Advanced Theranostic Nanoplatforms for Precision Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 31 January 2026 | Viewed by 57
Special Issue Editors
Interests: theranostic nanoplatforms; extracellular vesicle (EV); targeted drug delivery; stimuli-responsive nanomaterials; cancer and infectious disease therapy; antimicrobials; nanomedicine; biocompatible nanomaterials; real-time imaging; modular nanostructures; precision medicine; bacterial ghost (BG)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The integration of diagnostic and therapeutic functions into a single nanoplatform—theranostics—has become a transformative approach in personalized medicine. This Special Issue focuses on the development of modulable theranostic nanoplatforms based on synthetic nanosystems and engineered extracellular vesicles (EVs) for targeted delivery, real-time imaging, and controlled therapy, with particular relevance to cancer and infectious diseases.
Special attention will be given to EVs derived from both eukaryotic and bacterial sources, owing to their intrinsic biocompatibility, low immunogenicity, and natural targeting capabilities. In addition to EVs, bacterial ghosts (BGs)—non-living, empty bacterial envelopes created by controlled lysis—will be explored as innovative drug delivery systems. BGs retain the native surface structures of bacteria, facilitating targeted interaction with host cells, while offering high loading capacity and safety due to their non-replicative nature.
Alongside BGs, other biocompatible and stimuli-responsive nanomaterials will be investigated for their responsiveness to biological cues such as pH, enzymes, or redox gradients, enabling precise therapeutic action at diseased sites.
These multifunctional platforms will integrate diagnostic agents (e.g., fluorescent probes, MRI contrast agents) with therapeutic payloads (e.g., chemotherapeutics, antimicrobials, siRNA, or gene-editing tools) to enable simultaneous disease diagnosis and treatment.
Key objectives include the following:
- Fabrication of novel biocompatible nanomaterials for cancer and infectious disease therapy.
- Development of modular nanostructures with tunable properties for selective targeting.
- Integration of stimuli-responsive release mechanisms for controlled therapy.
- Validation of diagnostic potential using advanced in vitro and in vivo imaging.
- Evaluation of biocompatibility, biodistribution, and therapeutic efficacy in relevant models.
- Exploration of bacterial ghosts as a safe and effective platform for drug and gene delivery.
This Special Issue aims to provide a comprehensive overview of the latest innovations in theranostic nanomedicine, highlighting how these platforms are advancing precision treatment at the tissue, cellular, and subcellular levels.
Prof. Dr. Kwang-Sun Kim
Dr. Secheol Oh
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- theranostic nanoplatforms
- extracellular vesicles (EVs)
- targeted drug delivery
- stimuli-responsive nanomaterials
- antimicrobials
- cancer and infectious disease therapy
- nanomedicine
- biocompatible nanomaterials
- real-time imaging
- modular nanostructures
- precision medicine
- bacterial ghost
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
